Axon Enterprise, Inc. (NASDAQ:AXON) is Ulland Investment Advisors LLC’s 2nd Largest Position

Ulland Investment Advisors LLC lowered its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 31.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,939 shares of the biotechnology company’s stock after selling 6,931 shares during the period. Axon Enterprise accounts for 6.6% of Ulland Investment Advisors LLC’s investment portfolio, making the stock its 2nd biggest position. Ulland Investment Advisors LLC’s holdings in Axon Enterprise were worth $7,857,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in AXON. Vanguard Group Inc. grew its position in Axon Enterprise by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company’s stock valued at $5,019,886,000 after acquiring an additional 275,959 shares during the period. Geode Capital Management LLC grew its position in Axon Enterprise by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 1,847,925 shares of the biotechnology company’s stock valued at $1,095,542,000 after acquiring an additional 65,097 shares during the period. Capital World Investors grew its position in Axon Enterprise by 86.4% during the fourth quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company’s stock valued at $1,079,145,000 after acquiring an additional 841,772 shares during the period. Alliancebernstein L.P. grew its position in Axon Enterprise by 273.8% during the fourth quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company’s stock valued at $659,128,000 after acquiring an additional 812,337 shares during the period. Finally, Norges Bank acquired a new position in shares of Axon Enterprise during the fourth quarter worth about $482,081,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Axon Enterprise Trading Up 2.1%

Shares of NASDAQ AXON opened at $778.36 on Thursday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The stock’s 50 day moving average price is $658.49 and its two-hundred day moving average price is $619.52. The stock has a market capitalization of $60.60 billion, a P/E ratio of 201.13, a PEG ratio of 5.17 and a beta of 1.29. Axon Enterprise, Inc. has a 52-week low of $279.02 and a 52-week high of $806.64.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to analysts’ expectations of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business’s quarterly revenue was up 31.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.15 EPS. On average, analysts anticipate that Axon Enterprise, Inc. will post 5.8 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AXON has been the topic of a number of recent research reports. Barclays boosted their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research note on Friday, May 9th. Bank of America boosted their price objective on Axon Enterprise from $750.00 to $895.00 and gave the stock a “buy” rating in a research note on Wednesday, June 4th. Craig Hallum cut Axon Enterprise from a “buy” rating to a “cautious” rating in a research note on Monday, March 10th. Needham & Company LLC boosted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group boosted their price objective on Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $699.55.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the transaction, the chief executive officer now directly owns 3,063,982 shares of the company’s stock, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael Garnreiter sold 5,913 shares of the stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $760.00, for a total value of $4,493,880.00. Following the transaction, the director now directly owns 17,740 shares of the company’s stock, valued at approximately $13,482,400. The trade was a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,969 shares of company stock worth $29,909,594 in the last three months. 4.40% of the stock is owned by company insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.